Better Therapeutics, a leading developer of prescription digital therapeutics (PDTs) for managing cardiometabolic diseases, has recently made significant strides. The company announced the acceptance of a late-breaking abstract showcasing 180-day outcomes data from its AspyreRx pivotal trial. Additionally, Better Therapeutics is participating in the highly acclaimed 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, further solidifying its commitment to shaping the future of digital healthcare. Let s delve into the facts surrounding these developments and assess their impact on the company s trajectory.Better Therapeutics AspyreRx pivotal trial, foc...
In a remarkable stride towards the revolutionization of the healthcare industry, Better Therapeutics Inc., a flagbearer in the realm of prescription digital therapeutics (PDTs), has secured a significant rebate agreement with one of the top Pharmacy Benefit Managers (PBMs) in America. This move denotes an all-encompassing embrace of digital therapeutics as a new treatment paradigm in the country s healthcare landscape.Better Therapeutics, a member of the NASDAQ listing club under the ticker symbol BTTX, focuses on generating PDTs for effective treatment of cardiometabolic diseases. Its leading edge solution AspyreRx, designed to manage type 2 diabetes, has been given particular focus in the newly penned agre...
Leading Digital Health Pioneers, Better Therapeutics and Glooko, Forge Strategic Partnership to Propel Adoption of Innovative Type 2 Diabetes Treatment Across the U.S. Bolstering endeavors in digital health, Better Therapeutics Inc. (NASDAQ: BTTX), and Glooko, Inc., have announced a strategic partnership, marking a significant advancement in chronic disease management. This crucial collaboration resonates with the striving aim of both firms to integrate revolutionary solutions that will accelerate the adoption and efficacy of personalized diabetes treatment in the United States.Better Therapeutics, an innovative torchbearer in prescription digital therapeutics (PDTs), has been relentlessly working towards tr...
Sources:
Better Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Better Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Better Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
